Dr. Falk PharmaFalk Foundation
  • About us
    About us
    • Now into the future
    • Innovation drives everything
    • Why we are
    • Partnering
    • Corporate Sustainability
    • Following the footsteps of our founder
    • Global presence
  • Indications
    Indications
    • Crohn’s Disease
    • Eosinophilic Oesophagitis
    • Primary Biliary Cholangitis
    • Ulcerative colitis
  • Our products
  • News
  • Education centre
Search
Please choose your country
  • Global (English)
  • Australia
  • België (Vlaams)
  • Belgique (Français)
  • Deutschland
  • España
  • France
  • Ireland
  • Italia
  • Luxembourg (Français)
  • Nederland
  • Österreich
  • Portugal
  • Россия
  • Schweiz (Deutsch)
  • Suisse (Français)
  • United Kingdom
more info

Contact:
Phone:1800 DRFALK (1800 373 255) Email: admin@drfalkpharma.com.au

  • About us
  • Search
  • Contact us
  • Falk Foundation
  • For Healthcare Professionals
  • Reporting Adverse Events/Product Complaints
  • Reporting Suspected Misconduct
HCP Portal
  • About us
    • Now into the future
    • Innovation drives everything
    • Why we are
    • Partnering
    • Corporate Sustainability
    • Following the footsteps of our founder
    • Global presence
  • Indications
    • Crohn’s Disease
    • Eosinophilic Oesophagitis
    • Primary Biliary Cholangitis
    • Ulcerative colitis
  • Our products
  • News
  • Education centre
  • About us
  • Search
  • Contact us
  • Falk Foundation
  • For Healthcare Professionals
  • Reporting Adverse Events/Product Complaints
  • Reporting Suspected Misconduct
Contact:
Phone:
1800 DRFALK (1800 373 255)
Email:
admin@drfalkpharma.com.au
  • Homepage
  • Search

Search results

53 results

  • NEWSROOM
    Today is World IBD Day 2025
    IBD Has No Borders – Breaking Taboos, Talking About It.
  • NEWSROOM
    Strategic Partnership with Allianthera (Suzhou) Biopharmaceuticals
    for Novel AhR Agonist Development for the Treatment of Moderate to Severe Ulcerative Colitis
  • Now into the future
    Now into the future Homepage About us Now into the future Now into the future The future is created now. That's why Dr. Falk Pharma has a clear vision: Together more knowledge, more innovation, more…
  • NEWSROOM
    Merry Christmas
    ... and all the best for 2026!
  • Resources
    Salofalk Suppositories
  • Resources
    Salofalk enema
  • Resources
    Jorveza disintegrating tablets
  • «
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • »
Falk Foundation

Discover the range of continuing education opportunities for physicians and pharmacists provided by the Falk Foundation e.V.

Dr. Falk Pharma Australia

Dr. Falk Pharma is the expert in digestive and metabolic medicine. As a research-based family business with global presence, we focus on the development and distribution of innovative medicines that improve patients’ health and well-being. 

  • Falk Foundation
  • For Healthcare Professionals
  • Reporting Adverse Events/Product Complaints
  • Reporting Suspected Misconduct
  • Crohn’s Disease
  • Eosinophilic Oesophagitis
  • Primary Biliary Cholangitis
  • Ulcerative colitis
© 2026 Dr. Falk Pharma Australia Pty Ltd
  • Terms & conditions of use
Notice

This website is an international information resource intended for healthcare professionals outside the United States (US) and United Kingdom (UK).

I am a health care professional outside the US and UK.

Accept
Notice
I confirm I am a UK or Irish resident and have been prescribed either Budenofalk®, Jorveza®, Salofalk® or Ursofalk®
Accept

You are leaving the website of Dr. Falk Pharma in Australia.

We are not liable for the accuracy of any content published on third party websites – such as the one you are about to be forwarded to.